Jardim-Perassi B, Mu W, Huang S, Tomaszewski M, Poleszczuk J, Abdalah M
Theranostics. 2021; 11(11):5313-5329.
PMID: 33859749
PMC: 8039958.
DOI: 10.7150/thno.56595.
Maas A, Carter S, Wileyto E, Miller J, Yuan M, Yu G
Cancer Res. 2012; 72(8):2079-88.
PMID: 22374982
PMC: 3328659.
DOI: 10.1158/0008-5472.CAN-11-3744.
Chernikova S, Razorenova O, Higgins J, Sishc B, Nicolau M, Dorth J
Cancer Res. 2012; 72(8):2111-9.
PMID: 22354749
PMC: 3328627.
DOI: 10.1158/0008-5472.CAN-11-2209.
Chernikova S, Dorth J, Razorenova O, Game J, Brown J
Radiat Res. 2010; 174(5):558-65.
PMID: 20738173
PMC: 2988074.
DOI: 10.1667/RR2184.1.
Wang H, Van de Putte M, Chen F, De Keyzer F, Jin L, Yu J
Eur Radiol. 2008; 18(7):1422-30.
PMID: 18343928
DOI: 10.1007/s00330-008-0904-2.
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.
Ahn G, Brown J
Cancer Cell. 2008; 13(3):193-205.
PMID: 18328424
PMC: 2967441.
DOI: 10.1016/j.ccr.2007.11.032.
The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.
Madhu B, Waterton J, Griffiths J, Ryan A, Robinson S
Neoplasia. 2006; 8(7):560-7.
PMID: 16867218
PMC: 1601935.
DOI: 10.1593/neo.06319.
A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy.
Castano A, Liu Q, Hamblin M
Br J Cancer. 2006; 94(3):391-7.
PMID: 16421588
PMC: 2361144.
DOI: 10.1038/sj.bjc.6602953.
Application of 23Na MRI to monitor chemotherapeutic response in RIF-1 tumors.
Babsky A, Hekmatyar S, Zhang H, Solomon J, Bansal N
Neoplasia. 2005; 7(7):658-66.
PMID: 16026645
PMC: 1501427.
DOI: 10.1593/neo.05130.
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.
Bodell W, Giannini D, Singh S, Pietronigro D, Levin V
J Neurooncol. 2003; 62(3):251-8.
PMID: 12777076
DOI: 10.1023/a:1023383717833.
Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
Robinson S, McIntyre D, Checkley D, Tessier J, Howe F, Griffiths J
Br J Cancer. 2003; 88(10):1592-7.
PMID: 12771928
PMC: 2377119.
DOI: 10.1038/sj.bjc.6600926.
The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
Gallagher R, Hughes C, Murray M, Friery O, Patterson L, Hirst D
Br J Cancer. 2001; 85(4):625-9.
PMID: 11506506
PMC: 2364091.
DOI: 10.1054/bjoc.2001.1975.
Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia.
Collingridge D, Hill S, Chaplin D
Br J Cancer. 2001; 84(5):626-30.
PMID: 11237382
PMC: 2363803.
DOI: 10.1054/bjoc.2000.1650.
Use of thymidine analogues to indicate vascular perfusion in tumours.
BEGG A, Hofland I, Van Der Pavert I, Van der Schueren B, Haustermans K
Br J Cancer. 2000; 83(7):899-905.
PMID: 10970692
PMC: 2374690.
DOI: 10.1054/bjoc.2000.1372.
DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie M, Kovacs M, Gabalski E, Adam M, Le Q, Bloch D
Neoplasia. 2000; 1(5):461-7.
PMID: 10933062
PMC: 1508108.
DOI: 10.1038/sj.neo.7900060.
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Patterson L, McKeown S, Ruparelia K, Double J, Bibby M, Cole S
Br J Cancer. 2000; 82(12):1984-90.
PMID: 10864207
PMC: 2363261.
DOI: 10.1054/bjoc.2000.1163.
Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy.
Korbelik M, Parkins C, Shibuya H, Cecic I, Stratford M, Chaplin D
Br J Cancer. 2000; 82(11):1835-43.
PMID: 10839299
PMC: 2363231.
DOI: 10.1054/bjoc.2000.1157.
31P magnetic resonance spectroscopy as a predictor of efficacy in photodynamic therapy using differently charged zinc phthalocyanines.
BREMNER J, Wood S, Bradley J, Griffiths J, Adams G, Brown S
Br J Cancer. 1999; 81(4):616-21.
PMID: 10574246
PMC: 2362881.
DOI: 10.1038/sj.bjc.6690738.
Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).
Kuin A, Aalders M, Lamfers M, van Zuidam D, Essers M, Beijnen J
Br J Cancer. 1999; 79(5-6):793-801.
PMID: 10070871
PMC: 2362690.
DOI: 10.1038/sj.bjc.6690127.
31P-magnetic resonance spectroscopy and 2H-magnetic resonance imaging studies of a panel of early-generation transplanted murine tumour models.
Robinson S, van den Boogaart A, Maxwell R, Griffiths J, Hamilton E, Waterton J
Br J Cancer. 1998; 77(11):1752-60.
PMID: 9667643
PMC: 2150322.
DOI: 10.1038/bjc.1998.293.